Ireland
--:--IST
Latest
Clinical Trials in France / NCT05923736
Recruiting Not applicable

Cardiovascular Risk in Digital Osteoarthritis

NCT05923736 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2023-10-04
Last updated
2024-04-03

Condition(s) studied

Osteoarthritis HandLumbagoOsteoporosisRadiculopathy Lumbar

Investigational drug(s) / intervention(s)

Intima media thickness ultrasoundhand ultrasoundEndoPAT™ 2000 systemX-ray absorptiometry (DXA)

Intima media thickness ultrasound: EIM is a non-invasive ultrasound technique in which an ultrasound-generating probe is conventionally placed opposite the right primary carotid artery. By distinguishing between an inner layer, consisting of the intima and media, and the outer layer, the adventitia, the intima-media thickness can be assessed.

hand ultrasound: Performed by the rheumatologist, to quantify the number of synovial thickenings in B mode and the number of synovitis in Doppler mode. The presence or absence of joint erosions on the metacarpophalangeal (MCP), proximal interphalangeal (PPI) or distal interphalangeal (DIP) joints.

EndoPAT™ 2000 system: It's a measurement that detects endothelial dysfunction in coronary arteries using reactive hyperemia.This examination will be carried out in accordance with the manufacturer's instructions by the Rheumatology Department nurse. The patient lies down for the duration of the examination (20 minutes). A probe is placed on the index finger of each hand and a cuff on the left arm. Recording begins with a 5-minute baseline period (at rest), followed by a 5-minute period of arm occlusion, and ends with a 5-minute period of return to normal.

X-ray absorptiometry (DXA): This X-ray examination will be carried out on the Hologic device and the analyses by APEX 4.0 software. Two-photon X-ray absorptiometry (DXA) is a method commonly used to measure bone mineral density. It is based on a scan of the body by an X-ray beam at 2 different energy levels, which enables 3 compartments to be individualized: mineral mass, lean mass and fat mass. This low-radiation method (less than a conventional chest X-ray) is regarded as a benchmark for accurate measurement of both bone mineral density and the various body compartments. The examination lasts 10 minutes and is carried out by the department's electroradiology manipulators

Study summary

The goal of this cross-sectional case control study is to investigate the cardiovascular risk in digital osteoarthritis. This study aims to compare the cardiovascular risk between group of patients with digital osteoarthritis and control group of patients with non-osteoarthritis disease paired by measurement of carotid intima-media thickness. All participants will undergo an ultrasound scan to measure carotid intima media thickness, a clinical assessment with the rheumatologist and a cardiovascular risk assessment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: For all subjects: * Adult male or female subject * Able to give informed consent to participate in research * Affiliated with a Social Security plan For the digital osteoarthritis group: * Consultant in Rheumatology at Clermont-Ferrand University Hospital * Affected by digital osteoarthritis meeting ACR diagnostic criteria with radiographic signs of osteoarthritis validated by a radiologist. For the control group : * Rheumatology consultant at the Clermont-Ferrand University Hospital or hospitalized in this department for a non-arthritic, non-rheumatic pathology. * Patients with spinal disc pathology (lumbago, radiculalgia due to disco-radicular conflict) or non-severe osteoporosis, i.e. with a densitometric T score between -2.5 and -3 DS. Exclusion Criteria: For all topics : * Refusal to participate * Pregnant women, nursing mothers * Subjects under guardianship or curatorship, deprived of liberty, or under court protection For the digital osteoarthritis group: \- Existence of diagnostic arguments for another inflammatory rheumatism (rheumatoid arthritis, spondylarthritis, psoriatic arthritis, lupus, gout, chondrocalcinosis...) or another arthrosic localization (gonarthrosis, coxarthrosis, discarthrosis) symptomatic at the time of inclusion or affecting daily activities. For the control group : * Existence of chronic inflammatory rheumatism (rheumatoid arthritis, spondylitis, psoriatic arthritis, lupus, gout, chondrocalcinosis...) * Existence of digital osteoarthritis * Existence of another painful arthritic site (knee, hip, rachi) Existence of finger pain, whatever the etiology.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chu Clermont Ferrand Clermont-Ferrand France Recruiting

More University Hospital, Clermont-Ferrand trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05923736 on ClinicalTrials.gov ↗ ← All trials in France